<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H6FAE5AB54E56432CA7FD59F2C41A8DA0" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 8540 IH: Developing and Nationalizing Key Cannabis Research Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-07-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8540</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220727">July 27, 2022</action-date><action-desc><sponsor name-id="P000608">Mr. Peters</sponsor> (for himself and <cosponsor name-id="J000295">Mr. Joyce of Ohio</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to provide for the designation of institutions of higher education as Centers of Excellence in Cannabis Research, and for other purposes.</official-title></form><legis-body id="H9FCD9AC971504933986D425F7911CC16" style="OLC"> 
<section id="H31B2A8ABAFDD45429D0ED4E38C123F1A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Developing and Nationalizing Key Cannabis Research Act of 2022</short-title></quote>. </text></section> <section id="H150E58AC8FF64B458C9C277127A1A12C"><enum>2.</enum><header>Cannabis research at the Department of Health and Human Services</header> <subsection id="H96FF79E704D34361910D33BDD68C11BE"><enum>(a)</enum><header>National cannabis research agenda</header><text>Part B of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284 et seq.</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="H5ACE82C7CE004C87BF8B8D731302323C" style="OLC"> 
<section id="H42CDEB53457B4DF193288BFE7DCDA6A9"><enum>409K.</enum><header>National cannabis research agenda</header> 
<subsection id="HCE5F677B44294E27BF229E1C27DE217E"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of the <short-title>Developing and Nationalizing Key Cannabis Research Act of 2022</short-title>, the Director of NIH, in collaboration with the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, and the Assistant Secretary for Mental Health and Substance Use, shall develop a national cannabis research agenda that addresses key questions and gaps in evidence, including with respect to each of the following:</text> <paragraph id="HEE66998C381345218E279BA972D66C71"><enum>(1)</enum><text>The safety and efficacy of cannabis in providing therapeutic benefits for certain priority diseases or conditions, which may include epilepsy, multiple sclerosis-related spasticity, chemotherapy-induced pain and discomfort, using cannabis as an alternative to opioid analgesics for acute or chronic pain, sleep apnea, Tourette syndrome, anxiety, post-traumatic stress disorder, and any other disease or condition determined to be appropriate and of importance by the Director.</text></paragraph> 
<paragraph id="H338F707B6E0D44618A2164D3F8FAABDA"><enum>(2)</enum><text>The effect of cannabis on at-risk populations, including children, older individuals, and pregnant or breast-feeding women.</text></paragraph> <paragraph id="H6BFAE8D5380349CC8DE535644387C035"><enum>(3)</enum><text display-inline="yes-display-inline">The nontherapeutic impacts of cannabis use in the short-term and long-term.</text></paragraph> 
<paragraph id="H627466F6C2DB48F4AC0EA67B6D79DB44"><enum>(4)</enum><text>The long-term effects of cannabis use, including dose-response relationship and the connection between cannabis use and behavioral health.</text></paragraph> <paragraph id="H95BC53C6B8D64E3880B4D627F0A719FB"><enum>(5)</enum><text>The clinically appropriate dosages and modes of delivery of cannabis.</text></paragraph> 
<paragraph id="H3984E893E27F4CC099CF31B91411190D"><enum>(6)</enum><text>Public safety considerations related to cannabis, including—</text> <subparagraph id="HA1501DAD4DBE434FA532062EAF0DFF64"><enum>(A)</enum><text>variation in the potency of cannabis products;</text></subparagraph> 
<subparagraph id="H43CCE409D12344CA850C8F7EB3DE02A3"><enum>(B)</enum><text>youth access to and use of cannabis, including marketing, packaging, edible formulations, and flavor options that target youth;</text></subparagraph> <subparagraph id="HC96708F44665411E9D43517DF3924D4B"><enum>(C)</enum><text>risk factors for cannabis misuse;</text></subparagraph> 
<subparagraph id="HDFA5536B2FA04BC9A1BAA8975D6944E6"><enum>(D)</enum><text>impaired driving related to cannabis use;</text></subparagraph> <subparagraph id="H193F52103CDA4F58B8BAC51985FB7B22"><enum>(E)</enum><text>accidental ingestion of cannabis; and</text></subparagraph> 
<subparagraph id="H4AFDC0409699456794CD779EC92C406F"><enum>(F)</enum><text display-inline="yes-display-inline">relative risk of cannabis as compared to alcohol and tobacco.</text></subparagraph> </paragraph></subsection> <subsection id="H44E397536F934E79AD7443D6677461E8" commented="no"><enum>(b)</enum><header>Definition</header><text display-inline="yes-display-inline">In this section, the term <term>cannabis</term> means all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="HF3BA4F8A8604498FB2B9B557BB60A795"><enum>(b)</enum><header>Surveillance activities</header><text>Part A of title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/241">42 U.S.C. 241 et seq.</external-xref>) is amended by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H787C0F1D3B6F424BBBC9A85BFCB8217D" style="OLC"> <section id="HCE28CED8455F4019841F548FC3E77753"><enum>310B.</enum><header>Surveillance activities on cannabis use</header> <subsection id="H939C1CCC42C44F2291EB688E927CB9E0"><enum>(a)</enum><header>In general</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, in collaboration with the Assistant Secretary for Mental Health and Substance Use, the Administrator of the Centers for Medicare &amp; Medicaid Services, and the Director of the Agency for Healthcare Research and Quality, shall carry out surveillance activities to collect population-wide data on cannabis use.</text></subsection> 
<subsection id="HE3232423A3C14994BD400060AE2C5FEB"><enum>(b)</enum><header>Permissible activities</header> 
<paragraph id="H2ED18ED976974C588E46A587D05763DF"><enum>(1)</enum><header>In general</header><text>In carrying out activities under this section, the Secretary may collect, as appropriate, with respect to cannabis use—</text> <subparagraph id="HCFA1E19AAEA4408384ACC9E8A71782E8"><enum>(A)</enum><text>data on—</text> 
<clause id="HCA3A2F60649442A592A628663DD9638A"><enum>(i)</enum><text>health outcomes, including biological data;</text></clause> <clause id="H91CD1FD46521416DB9B5715EA5D59FA5"><enum>(ii)</enum><text>health care utilization, which shall include hospitalizations and utilization of emergency departments related to consumption of cannabis, including among youth;</text></clause> 
<clause id="H8CB5D7EE0F8D4B86AD635E168053112E"><enum>(iii)</enum><text>demographic factors associated with cannabis use;</text></clause> <clause id="HE222EA22889F4230879A6C479A2B4DCA"><enum>(iv)</enum><text>the variety of products and delivery modes used; and</text></clause> 
<clause id="H41C09D592DE04B2FAC0B6151C7C683F6"><enum>(v)</enum><text>other relevant health information to improve the understanding of cannabis use in all age groups and sub-populations; and</text></clause></subparagraph> <subparagraph id="HB0D50F02E6784F5AA6D9CCA4596A5B2A"><enum>(B)</enum><text>data through public health surveillance systems, surveys, questionnaires, and databases of health care records, including, as appropriate, the Behavioral Risk Factor Surveillance System, the Youth Risk Behavioral Surveillance System, the Monitoring the Future health survey, the National Survey on Drug Use and Health, or the Healthcare Cost and Utilization Project (or any successor surveys).</text></subparagraph></paragraph> 
<paragraph id="H0D217DE309DF4B0E82BDB31E6B421732"><enum>(2)</enum><header>Privacy</header><text>Any data collected under paragraph (1) shall be collected in manner that protects personal privacy to the extent, at a minimum, that is required under applicable Federal and State law.</text></paragraph></subsection> <subsection id="HCAA772B52EF341AFA4D1BCEAC79CFCBA"><enum>(c)</enum><header>Definition</header><text display-inline="yes-display-inline">In this section, the term <term>cannabis</term> means all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section> 
<section id="H61D1DCC8C0374C4BB94148E9ED3B3F55"><enum>3.</enum><header>Centers of Excellence in Cannabis Research</header> 
<subsection id="HD9ACF7BD69C246249A8E2631F674865D"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Part B of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284 et seq.</external-xref>), as amended by section 2, is further amended by adding at the end the following:</text> <quoted-block id="HF9A0E3F3ADEF43419765F7DD659B1BB0" style="OLC"> <section id="H4BECF1EA10184A2AA331713D3429B43F"><enum>409L.</enum><header>Centers of Excellence in Cannabis Research</header> <subsection id="HE4F02536682748BC80FA0AD9AA392514"><enum>(a)</enum><header>Designation</header> <paragraph id="H43C86E2E37744559BF441E708B03EA51"><enum>(1)</enum><header>In general</header><text>The Director of NIH shall designate institutions of higher education as Centers of Excellence in Cannabis Research for the purpose of interdisciplinary research related to cannabis and other biomedical, behavioral, and social issues related to cannabis.</text></paragraph> 
<paragraph id="H53719E386B5E48FF987D3B75D16D78CA"><enum>(2)</enum><header>Application</header><text display-inline="yes-display-inline">To be designated as a Center of Excellence in Cannabis Research, an institution of higher education shall submit an application to, and receive approval from, the Director of NIH. Such an application shall be submitted in such manner and contain such information as the Director of NIH may reasonably require. The Director of NIH may not approve such an application unless—</text> <subparagraph id="H1264AE29DE6D4EF5A1D5120A81A55989"><enum>(A)</enum><text>the application contains or is supported by reasonable assurances that—</text> 
<clause id="HE68438297947453E846B9485367F3BEB"><enum>(i)</enum><text>the applicant has the experience, or capability—</text> <subclause id="H1F7B3A11F46B4AB999F6D2F38D95A744"><enum>(I)</enum><text>to conduct, through biomedical, behavioral, social, and related disciplines, long-term research on cannabis; and</text></subclause> 
<subclause id="H16B5C9BDF5B14B02AE7F33169AC1064D"><enum>(II)</enum><text>to provide coordination of such research among such disciplines;</text></subclause></clause> <clause id="H126D33CA51F84676AC8E726E8088DF38"><enum>(ii)</enum><text>the applicant has available to it sufficient personnel and facilities (including laboratory, reference, storage, security, and data analysis facilities) to carry out the research plan required under subparagraph (B);</text></clause> 
<clause id="HDE4754780AB346E8A0CA0B63D289B8CA"><enum>(iii)</enum><text>the applicant has the capacity to conduct academic courses and train students and professionals on appropriate research and knowledge of cannabis; and</text></clause> <clause id="H6D078D625FAB41EE891D7041AC7E14B6"><enum>(iv)</enum><text display-inline="yes-display-inline">the applicant will secure State funds for research related to cannabis to complement any Federal funds for such research under this section; and</text></clause></subparagraph> 
<subparagraph id="H35E14BF3FD5043BFBAA90D30493E065C"><enum>(B)</enum><text display-inline="yes-display-inline">the application contains a detailed 5-year plan for research relating to cannabis.</text></subparagraph></paragraph> <paragraph id="HDDAC50956FC84840A5349E5663BE3CC0"><enum>(3)</enum><header>Priority</header><text display-inline="yes-display-inline">In selecting institutions of higher education for designation as Centers of Excellence in Cannabis Research, the Director of NIH shall give priority to such institutions that have proven track records in medicinal cannabis research.</text></paragraph> 
<paragraph id="H369440DF719D4BB297775A1DD6EB6CFB"><enum>(4)</enum><header>Geographic representation</header><text>The Director of NIH shall, to the extent practicable, ensure geographic representation across the United States in designating institutions of higher education as Centers of Excellence in Cannabis Research.</text></paragraph> <paragraph id="H209ACD101C9545AB8B1469B96B4B3A96"><enum>(5)</enum><header>Term of designation</header><text>A designation under this section shall be for a period of 5 years, so long as the institution of higher education continues to meet the requirements of paragraph (2). An institution of higher education may reapply in accordance with the requirements of paragraph (2) for a subsequent designation under this section.</text></paragraph></subsection> 
<subsection id="HAF1B43CC8CCB4BB083A255940F5BAC01"><enum>(b)</enum><header>Cannabis research</header> 
<paragraph id="HC8001A789AEB498EB734A3EDDA492811"><enum>(1)</enum><header>Grants or cooperative agreements</header> 
<subparagraph id="HCF40D133842B4149AE12932FFEE6FA2B"><enum>(A)</enum><header>In general</header><text>The Director of NIH may make grants to, or enter into cooperative agreements with, 10 Centers that have been designated under this section to expand the current and ongoing interdisciplinary research and clinical trials relating to cannabis research.</text></subparagraph> <subparagraph id="H4E53CEA871AB4DF19D4A7194C601264D"><enum>(B)</enum><header>Authorization of appropriations</header><text>To carry out this paragraph, there is authorized to be appropriated $50,000,000 for each of fiscal years 2024 through 2028.</text></subparagraph></paragraph> 
<paragraph id="HDCCD61D680D348E9969C7A0B14051CC0"><enum>(2)</enum><header>Research results</header><text>The Director of NIH shall promptly disseminate research results under this subsection to relevant governmental, academic, and research entities.</text></paragraph></subsection> <subsection id="HEE5BD586CA5F40DEA0EF008FA8C683FB"><enum>(c)</enum><header>Definitions</header><text>In this section:</text> 
<paragraph id="H0136C1F83A254A94BE529D72BFE318B4"><enum>(1)</enum><text display-inline="yes-display-inline">The term <term>cannabis</term> means all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. </text></paragraph> <paragraph id="H847F2D9D003D4468A8735724F6E51747"><enum>(2)</enum><text>The term <term>institution of higher education</term> has the meaning given the term in section 101(a) of the Higher Education Act of 1965.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="HCC8E9D771EFC474AA32E77F410E618F8"><enum>(b)</enum><header>Registration requirements</header><text display-inline="yes-display-inline">Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended by adding at the end the following:</text> <quoted-block style="OLC" id="H95B463B9D2F0476DB33B61563CAF61C2" display-inline="no-display-inline"> <subsection id="HB0B15AAD9D714032B71A6DB6F2C35046"><enum>(l)</enum><header>Registration of practitioners at Centers of Excellence in Cannabis Research</header> <paragraph id="H04FCAC8043274BBD94BF2EF467AAA726"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Attorney General shall register under subsection (f) practitioners at Centers of Excellence in Cannabis Research designated under section 409L of the Public Health Service Act to conduct research with marijuana.</text></paragraph> 
<paragraph id="H9A46979183304171823862A702D6B965"><enum>(2)</enum><header>Testing of constituents</header><text display-inline="yes-display-inline">To the extent a Center of Excellence in Cannabis Research in a State tests marijuana products that are lawfully available for such testing in such State for cannabinoid and noncannabinoid constituents, no sanction under this title shall apply to such testing, including the acquisition of such products for such testing.</text></paragraph> <paragraph id="H527A7E1DCC61431BB065058472E9ED7A"><enum>(3)</enum><header>Use of marijuana products under State law</header><text display-inline="yes-display-inline">No sanction under this title shall apply to the acquisition or use of marijuana products for a clinical trial or other research to the extent such clinical trial or other research is conducted—</text> 
<subparagraph id="H2F94AA68D6D6459A9A321B2993161925"><enum>(A)</enum><text>to further the goals of the national cannabis research agenda under section 409K; and</text></subparagraph> <subparagraph id="H7E2CF829CDCD477D854D35CFF7F7F455"><enum>(B)</enum><text>at a Center of Excellence in Cannabis Research in a State using marijuana products that are lawfully available for such purpose under laws of the State.</text></subparagraph></paragraph> 
<paragraph id="HF7793323B5AC413E8ECAB2FB5A9C202F"><enum>(4)</enum><header>Definition</header><text display-inline="yes-display-inline">In this subsection, the term <term>Center of Excellence in Cannabis Research</term> means a Center of Excellence in Cannabis Research for which a designation is in effect under section 409L(a) of the Public Health Service Act.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section> </legis-body></bill>

